GGrantIndex
← Leaderboards

Robert A Seder

Niaid Extramural Activities

$55,743
Attributed
$55,743
Total exposure
1
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$55,743 · 1

By mechanism

P51$55,743 · 1

Top collaborators

No co-investigators on record.

Most similar at Niaid Extramural Activities

Same institution · by research overlap

Others in their field

Top investigators on “Immunity

Research focus

ImmunityVaccinesInfectionT-LymphocyteResponseVaccine DevelopmentProteinsImmuneImmunizationAntibodiesAdjuvantImmune ResponseImmunogenicityVaccinationCd8b1 GeneT Cell ResponseAntigensMalariaMediatingNonhuman PrimateIn VivoAttenuatedCytokineRoute

Grant awards (72)

Development of Pre-Erythrocytic Malaria Vaccines and antibodies$1,663,887
ZIA · FY2025 · AI · contact PI
Cancer Vaccines and Immunotherapy$1,327,187
ZIA · FY2025 · AI · contact PI
Development of Vaccines to Prevent Tuberculosis$903,787
ZIA · FY2025 · AI · contact PI
Development of Vaccines to Prevent Tuberculosis$1,680,146
ZIA · FY2024 · AI · contact PI
Development of a COVID Vaccine Model in NHP$845,146
ZIA · FY2024 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines and antibodies$422,573
ZIA · FY2024 · AI · contact PI
Development of Vaccines to Prevent Tuberculosis$1,056,433
ZIA · FY2023 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines and antibodies$1,056,433
ZIA · FY2023 · AI · contact PI
Development of a COVID Vaccine Model in NHP$332,304
ZIA · FY2023 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines and antibodies$1,584,649
ZIA · FY2022 · AI · contact PI
Development of Vaccines to Prevent Tuberculosis$528,216
ZIA · FY2022 · AI · contact PI
Development of a COVID Vaccine Model in NHP$332,304
ZIA · FY2022 · AI · contact PI
Development of Vaccines to Prevent Tuberculosis$2,490,549
ZIA · FY2021 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines and antibodies$1,056,433
ZIA · FY2021 · AI · contact PI
Development of a COVID Vaccine Model in NHP$250,000
ZIA · FY2021 · AI · contact PI
Development of Vaccines to Prevent Tuberculosis$1,847,416
ZIA · FY2020 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$1,106,483
ZIA · FY2020 · AI · contact PI
Development of a COVID Vaccine Model in NHP$350,000
ZIA · FY2020 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$1,680,701
ZIA · FY2019 · AI · contact PI
Development of Vaccines to Prevent Tuberculosis$1,680,701
ZIA · FY2019 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$3,223,147
ZIA · FY2018 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$1,553,207
ZIA · FY2018 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$5,012,423
ZIA · FY2017 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$2,423,669
ZIA · FY2017 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$2,392,577
ZIA · FY2016 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$1,024,485
ZIA · FY2016 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$4,186,577
ZIA · FY2015 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$524,485
ZIA · FY2015 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$195,037
ZIA · FY2015 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$4,186,577
ZIA · FY2014 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$524,485
ZIA · FY2014 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$195,037
ZIA · FY2014 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$4,186,577
ZIA · FY2013 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$210,038
ZIA · FY2013 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$195,037
ZIA · FY2013 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$4,186,577
ZIA · FY2012 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$210,038
ZIA · FY2012 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$195,037
ZIA · FY2012 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$3,196,577
ZIA · FY2011 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$685,038
ZIA · FY2011 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$685,037
ZIA · FY2011 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$3,205,924
ZIA · FY2010 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$686,986
ZIA · FY2010 · AI · contact PI
Development of Pre-Erythrocytic Malaria Vaccines$686,983
ZIA · FY2010 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$1,641,899
ZIA · FY2009 · AI · contact PI
Factors Regulating T Helper Cell Memory Differentiation$1,641,899
ZIA · FY2009 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$1,641,899
ZIA · FY2009 · AI · contact PI
VACCINE DEVELOPMENT FOR TUBERCULOSIS$55,743
P51 · FY2009 · RR · contact PI
Development Of A Vaccine For Leishmania Major Infection$557,449
Z01 · FY2008 · AI · contact PI
Factors Regulating T Helper Cell Memory Differentiation$557,449
Z01 · FY2008 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$557,449
Z01 · FY2008 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$621,788
Z01 · FY2007 · AI · contact PI
Factors Regulating T Helper Cell Memory Differentiation$621,788
Z01 · FY2007 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$621,788
Z01 · FY2007 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$0
Z01 · FY2006 · AI · contact PI
Factors Regulating T Helper Cell Memory Differentiation$0
Z01 · FY2006 · AI · contact PI
Optimization Of HIV Specific Immune Responses In Vivo$0
Z01 · FY2006 · AI · contact PI
Development Of A Vaccine For Leishmania Major Infection$0
Z01 · FY2005 · AI
Factors Regulating T Helper Cell Memory Differentiation$0
Z01 · FY2005 · AI
Optimization Of HIV Specific Immune Responses In Vivo$0
Z01 · FY2005 · AI
Development Of A Vaccine For Leishmania Major Infection$0
Z01 · FY2004 · AI
Factors Regulating T Helper Cell Memory Differentiation$0
Z01 · FY2004 · AI
Optimization Of HIV Specific Immune Responses In Vivo$0
Z01 · FY2004 · AI
Development Of A Vaccine For Leishmania Major Infection$0
Z01 · FY2003 · AI
Factors Regulating T Helper Cell Memory Differentiation$0
Z01 · FY2003 · AI
Optimization Of HIV Specific Immune Responses In Vivo$0
Z01 · FY2003 · AI
Development Of A Vaccine For Leishmania Major Infection$0
Z01 · FY2002 · AI
Factors Regulating T Helper Cell Memory Differentiation$0
Z01 · FY2002 · AI
Optimization Of Hiv Specific Immune Responses In Vivo$0
Z01 · FY2002 · AI
REGULATION OF CYTOKINE PRODUCTION FROM PATIENTS INFECTED W/HIV &TB$0
Z01 · FY2000 · AI
DNA VACCINATION FOR PREVENTION OF VIRAL, PARASITIC AND MYCOBACTERIAL INFECTION$0
Z01 · FY2000 · AI
CYTOKINE REGULATION IN ANIMALS INFECTED WITH HISTOPLASMA CAPSULATUM$0
Z01 · FY2000 · AI